Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease

Vaccine

Volumn 29, Issue 1, 2010, Pages 51-57

  Govender, Lerisa ^a   Abel, Brian ^a   Hughes, E Jane ^a   Scriba, Thomas J ^a   Kagina, Benjamin M N ^a   de Kock, Marwou ^a   Walzl, Gerhard ^b   Black, Gillian ^b   Rosenkrands, Ida ^c   Hussey, Gregory D ^a   Mahomed, Hassan ^a   Andersen, Peter ^a   Hanekom, Willem A ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

Latency antigens; LTBI; Mycobacterium tuberculosis; Post infection vaccine; TB disease

Indexed keywords

BACTERIAL ANTIGEN; BCG VACCINE; GAMMA INTERFERON; RV 2659; RV 2660; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL VIABILITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; LATENT TUBERCULOSIS; LYMPHOCYTE PROLIFERATION; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL;

ADULT; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; HUMANS; INTERFERON-GAMMA; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 78649693679     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.022     Document Type: Article

References (25)

1. Andersen P. Vaccine strategies against latent tuberculosis infection. Trends Microbiol 2007, 15(January (1)):7-13.
2. Flynn J.L., Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001, 19:93-129.
3. Corbett E.L., Watt C.J., Walker N., Maher D., Williams B.G., Raviglione M.C., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003, 163(May (9)):1009-1021.
4. Organisation WH Global tuberculosis control-surveillance, planning, financing 2008, World Health Organisation, Geneva, Switzerland.
5. Baumann S., Nasser Eddine A., Kaufmann S.H. Progress in tuberculosis vaccine development. Curr Opin Immunol 2006, 18(August (4)):438-448.
6. Sherman D.R., Voskuil M., Schnappinger D., Liao R., Harrell M.I., Schoolnik G.K. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin. Proc Natl Acad Sci USA 2001, 98(June (13)):7534-7539.
7. Betts J.C., Lukey P.T., Robb L.C., McAdam R.A., Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002, 43(February (3)):717-731.
8. Gordon S.V., Eiglmeier K., Garnier T., Brosch R., Parkhill J., Barrell B., et al. Genomics of Mycobacterium bovis. Tuberculosis (Edinb) 2001, 81(1-2):157-163.
9. Black G.F., Fine P.E.M., Warndorff D.K., Floyd S., Weir R.E., Blackwell J.M., et al. Relationship between IFN-gamma and skin test responsiveness to Mycobacterium tuberculosis PPD in healthy, non-BCG-vaccinated young adults in Northern Malawi. Int J Tuberc Lung Dis 2001, 5(July (7)):664-672.
10. Abu-Raddad L.J., Sabatelli L., Achterberg J.T., Sugimoto J.D., Longini I.M., Dye C., et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA 2009, 106(August (33)):13980-13985.
11. Schuck S.D., Mueller H., Kunitz F., Neher A., Hoffmann H., Franken K.L., et al. Identification of T-cell antigens specific for latent Mycobacterium tuberculosis infection. PLoS One 2009, 4(5):e5590.
12. Tully G., Kortsik C., Hohn H., Zehbe I., Hitzler W.E., Neukirch C., et al. Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infection. J Immunol 2005, 174(February (4)):2174-2184.
13. Fiorenza G., Rateni L., Farroni M.A., Bogue C., Dlugovitzky D.G. TNF-alpha, TGF-beta and NO relationship in sera from tuberculosis (TB) patients of different severity. Immunol Lett 2005, 98(April (1)):45-48.
14. Guyot-Revol V., Innes J.A., Hackforth S., Hinks T., Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 2006, 173(April (7)):803-810.
15. Ordway D.J., Martins M.S., Costa L.M., Freire M.S., Arroz M.J., Dockrell H.M., et al. Increased IL-4 production in response to virulent Mycobacterium tuberculosis in tuberculosis patients with advanced disease. Acta Med Port 2005, 18(January-February (1)):27-36.
16. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439(February (7077)):682-687.
17. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443(September (7109)):350-354.
18. van Grevenynghe J., Procopio F.A., He Z., Chomont N., Riou C., Zhang Y. Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med 2008, 14(March (3)):266-274.
19. Barry C.E., 3rd, Boshoff H.I., Dartois V., Dick T., Ehrt S., et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7(December (12)):845-855.
20. Forbes E.K., Sander C., Ronan E.O., McShane H., Hill A.V., Beverley P.C., et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008, 181(October (7)):4955-4964.
21. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009, 182(June (12)):8047-8055.
22. Makedonas G., Betts M.R. Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection. Springer Semin Immunopathol 2006, 28(November (3)):209-219.
23. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8(April (4)):247-258.
24. Andersen P. Tuberculosis vaccines-an update. Nat Rev Microbiol 2007, 5(July (7)):484-487.
25. van Dissel J.T., Arend S.M., Prins C., Bang P., Tingskov P.N., Lingnau K., et al. Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010, 28(April (20)):3571-3581.